Product logins

Find logins to all Clarivate products below.


Population Health Management in Type 2 Diabetes: What Does This Approach Mean for Specific Diabetes Brands? | Physician & Payer Forum | US | 2014

Population health management (PHM) represents one of the long-term goals of the healthcare industry: building upon the patient-centered medical home concept to provide proactive support to a defined patient population in an attempt to address preventable behaviors that drive up healthcare costs. Through process improvement aided by technology, PHM helps with clinical decision support, thus improving the quality of care as well as patient safety. In diabetes, PHM is an attractive target for the following reasons: its ability to stratify patient populations, the disease’s high prevalence and costs, concerns over patient noncompliance, the risk of hospitalization associated with the disease, and the presence of defined treatment algorithms.

PHM is geared toward high-risk individuals and changes in physician compensation (partly tied to the proliferation of accountable care organizations) are translating into changes in prescribing behavior. As the use of PHM becomes more ingrained in physicians’ practice behavior, specific therapies will gain market share at the expense of others.

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…